CD30 expression in non-lymphomatous malignancies (Abstract #3069)In a screening study, assessment of CD30 expression was performed in patients who had a non-lymphoma malignancy and were relapsed or refractory to previous therapy, or had no alternative curative treatment option available. Patients with CD30 expression were eligible for a companion phase II clinical trial. Per the screening protocol, patients were considered to be CD30-positive and eligible for the companion clinical trial if at least 10 percent of malignant cells were positive by immunohistochemistry or at least 20 percent of malignant cells were positive by flow cytometry. At the time of data analysis, a total of 1,637 patients had been screened. Key findings include:
- Thirty-eight patients (2 percent) and 17 different malignant diagnoses were CD30 positive per protocol.
- The most common malignancies with CD30 expression were mesothelioma (5 of 18 patients; 28 percent), melanoma (6 of 64 patients; 9 percent), triple negative breast cancer (4 of 71 patients; 6 percent) and ovarian carcinoma (9 of 173 patients; 5 percent).
- Assessment of CD30 expression under the screening protocol is ongoing with target enrollment of up to 3,000 patient tumor samples.
- A phase II companion treatment protocol is ongoing to characterize the antitumor activity of ADCETRIS in patients with CD30-positive non-lymphoma malignancies and to correlate expression with activity.
- Monday, June 4; 8:00 a.m. to 12:00 p.m. CT
- S Hall A2; poster board #16C
- First author: Dr. Jeff P. Sharman, Willamette Valley Center Institute and Research Center, Eugene, OR